http://jpet.aspetjournals.org/content/jpet/371/1/1.full.pdf … This is big news; an antipsychotic that's NOT a D2 agonist.
-
-
It's a high-tech version of what psychopharmacology used to be like in the 1950's -- give some chemicals to mice and see if they act funny. This allows the discovery of totally new mechanisms of action.
Show this thread -
I learned about this from Emer Leahy, the founder of Psychogenics, the biotech company that built the SmartCube and pioneered this behavioral-phenotype approach to CNS drug discovery. It sounded crazy 20 years ago, but now the results are coming in and they're astonishing.
Show this thread -
In vivo phenotypic screening: it's how you do exploratory science when computing power is abundant! And it works! (Hint: we're doing it at Daphnia Labs too.)
Show this thread
End of conversation
New conversation -
-
-
Do you know how they select drugs to test in the SmartCube?
-
They started with a standard library of psychoactive drugs to validate/calibrate the platform, and then they partnered with pharma companies to screen their libraries.
- 4 more replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.